CagriSema Demonstrates Significant Weight Loss in Adults with Obesity
Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type 2 diabetes who have overweight or obesity. The studies were presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in the New England Journal of Medicine. Nearly 90% of U.S. adults who have diabetes also have overweight or obesity, underscoring the close link between excess weight and the development or progression of type 2 diabetes. While treatment options for obesity and type 2 diabetes have progressed with glucagon-like peptide-1 (GLP-1) receptor agonists, there is an ongoing need for therapies that can address weight and glucose management together. CagriSema, the dual agonist studied in REDEFINE 1 and 2, is…
